Tumor hypoxia: Molecular pathways and therapeutic interventions

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Tumor hypoxia is a critical factor promoting cancer progression, resistance to therapy, and immune evasion.
• Hypoxic conditions create unique vulnerabilities within tumors that can be therapeutically exploited.

Purpose of the Study:

• To review current and emerging strategies targeting tumor adaptation to hypoxia.
• To summarize agents, mechanisms, clinical status, and lessons learned from hypoxia-targeted therapies.

Main Methods:

• Comprehensive review of literature on hypoxia-targeted cancer therapies.
• Analysis of hypoxia-activated prodrugs, HIF inhibitors, and novel non-HIF targeting approaches.
• Evaluation of clinical development status and challenges.

Main Results:

• Multiple strategies exist, including hypoxia-activated prodrugs and HIF inhibitors, targeting hypoxic tumor vulnerabilities.
• Emerging approaches target oxygen-sensing enzymes, chromatin modifiers, metabolic pathways, and the unfolded protein response.
• Clinical translation is hindered by hypoxia heterogeneity, drug activation issues, and patient selection challenges.

Conclusions:

• Targeting tumor hypoxia offers promising therapeutic avenues but faces significant clinical translation hurdles.
• Improved hypoxia biomarkers, imaging, profiling, and combination strategies are crucial for precision deployment of these therapies.